Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Efficacy of Mirabegron, Solifenacin, Tadalafil 5mg and Combination Therapy in Female Patients With Overactive Bladder: A Double Blinded Prospective Randomized Placebo -Controlled Trial

NCT06184334 is registered in ClinicalTrials.gov with Elsayed Abdelhalim Elsayed as lead sponsor.

NCT NCT06184334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06184334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Efficacy of Mirabegron, Solifenacin, Tadalafil 5mg and Combination Therapy in Female Patients With Overactive Bladder: A Double Blinded Prospective Randomized Placebo -Controlled Trial
Lead sponsor
Elsayed Abdelhalim Elsayed
Phase
Not applicable
Overall status
Completed
Start date
September 14, 2022
Completion date
December 1, 2023
Enrollment
300 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder